Trial: 201911138

A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Phase

I (Cancer Control)

Principal Investigator

Morgensztern, Daniel

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov